Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.

Moss, TJ; Ahnert, JR; Oakley, HD; Kahle, M; Karp, DD; Pant, S; Jacob, J; Raymond, VM; Lanman, RB; Kwong, L; Routbort, M; Soni, N; Huang, J; Javle, MM; Meric-Bernstam, F

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索